CureVac gets first mRNA vaccine data in humans; waits for next step
This article was originally published in Scrip
CureVac, a small mRNA vaccine company in Tuebingen, Germany has shown that its CV9301 product for hormone-refractory prostate cancer is safe, well-tolerated and can elicit both a cellular and humoral immune response in a a high percentage of trial subjects. The data, from an open lable Phase I/IIa trial, announced on 4 October, are the company's first clinical results but the company now plans to wait for further results from an ongoing Phase I trial of a second product, CV9201 in non-small cell lung cancer before finalising its development strategy. "What is clear is that we don't stop here," said CEO Mr Ingmar Hoerr. "But how the product goes forward is unclear." The company will follow the prostate cancer patient outcomes for a year and then decide on its strategy. He explained that CureVac saw the results on CV9103 as the proof of concept that mRNA-based vaccines can stimulate a human immune response against a range of antigens.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.